侵袭性B细胞淋巴瘤-话题@MedSci

#侵袭性B细胞淋巴瘤#

9篇内容 | 1274人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2257202, encodeId=e1e5225e20225, content=<a href='/topic/show?id=35a050454a5' target=_blank style='color:#2F92EE;'>#循环肿瘤DNA#</a> <a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=【JAMA Oncol】循环肿瘤DNA在侵袭性B细胞淋巴瘤MRD评估中大有可为, objectType=article, longId=868201, objectId=a8e7868201f3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250224/1740391727298_8538692.jpg, objectUrl=/article/show_article.do?id=a8e7868201f3, replyNumber=0, likeNumber=12, createdTime=2025-03-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=a8e7868201f3, moduleTitle=【JAMA Oncol】循环肿瘤DNA在侵袭性B细胞淋巴瘤MRD评估中大有可为, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8e7868201f3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2207069, encodeId=8fd1220e069c1, content=<a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=【Hemasphere】CAR-T等新疗法显著改善了R/R侵袭性B细胞淋巴瘤生存：西班牙真实世界研究, objectType=article, longId=827816, objectId=830482e816e5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240528/1716876996548_5579292.jpg, objectUrl=/article/show_article.do?id=830482e816e5, replyNumber=0, likeNumber=111, createdTime=2024-05-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=830482e816e5, moduleTitle=【Hemasphere】CAR-T等新疗法显著改善了R/R侵袭性B细胞淋巴瘤生存：西班牙真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=830482e816e5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2196846, encodeId=39c32196846e7, content=<a href='/topic/show?id=f6435e4216a' target=_blank style='color:#2F92EE;'>#放疗#</a> <a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=【Leukemia】放疗可改善年轻高危侵袭性B细胞淋巴瘤患者预后, objectType=article, longId=819980, objectId=0ef38199800f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PTE4SCK.jpg, objectUrl=/article/show_article.do?id=0ef38199800f, replyNumber=0, likeNumber=109, createdTime=2024-04-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=0ef38199800f, moduleTitle=【Leukemia】放疗可改善年轻高危侵袭性B细胞淋巴瘤患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ef38199800f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2070916, encodeId=1bef20e0916be, content=<a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较, objectType=article, longId=298991, objectId=961f298991d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=961f298991d8, replyNumber=0, likeNumber=96, createdTime=2022-07-11, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961f298991d8, moduleTitle=NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961f298991d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2070915, encodeId=1f2520e091548, content=<a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后, objectType=article, longId=217065, objectId=6c6c21e06592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c6c21e06592, replyNumber=0, likeNumber=75, createdTime=2022-06-23, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c6c21e06592, moduleTitle=Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c6c21e06592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2070914, encodeId=059d20e091440, content=<a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效, objectType=article, longId=212401, objectId=f48f21240133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f48f21240133, replyNumber=0, likeNumber=98, createdTime=2021-09-26, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f48f21240133, moduleTitle=Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f48f21240133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2070913, encodeId=a38520e0913b8, content=<a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效, objectType=article, longId=196009, objectId=77a7196009ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77a7196009ec, replyNumber=0, likeNumber=76, createdTime=2021-02-15, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77a7196009ec, moduleTitle=Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77a7196009ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2070911, encodeId=80c520e091157, content=<a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=CLIN CANCER RES：克服侵袭性B细胞淋巴瘤Venetoclax耐药策略, objectType=article, longId=147811, objectId=c09f14e81109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c09f14e81109, replyNumber=0, likeNumber=78, createdTime=2018-09-10, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c09f14e81109, moduleTitle=CLIN CANCER RES：克服侵袭性B细胞淋巴瘤Venetoclax耐药策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c09f14e81109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2070912, encodeId=fd9120e0912b0, content=<a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=Lancet Haematol：MYC基因重排侵袭性B细胞淋巴瘤可考虑剂量调整的EPOCH-R方案, objectType=article, longId=158333, objectId=632d1583337f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632d1583337f, replyNumber=0, likeNumber=76, createdTime=2019-04-01, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632d1583337f, moduleTitle=Lancet Haematol：MYC基因重排侵袭性B细胞淋巴瘤可考虑剂量调整的EPOCH-R方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=632d1583337f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2070910, encodeId=11d820e09106e, content=<a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=MYC基因异常的侵袭性B细胞淋巴瘤, objectType=article, longId=33867, objectId=96593386e81, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96593386e81, replyNumber=0, likeNumber=82, createdTime=2015-01-01, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96593386e81, moduleTitle=MYC基因异常的侵袭性B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96593386e81)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2070909, encodeId=671920e0909ab, content=<a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=Lancet Oncol：R-MegaCHOEP方案无益于年轻高危侵袭性B细胞淋巴瘤患者（(DSHNHL 2002-1研究）, objectType=article, longId=11320, objectId=310a11320c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=310a11320c6, replyNumber=0, likeNumber=85, createdTime=2013-04-09, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=310a11320c6, moduleTitle=Lancet Oncol：R-MegaCHOEP方案无益于年轻高危侵袭性B细胞淋巴瘤患者（(DSHNHL 2002-1研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=310a11320c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2070908, encodeId=db0b20e090835, content=<a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵袭性B细胞淋巴瘤#</a>, objectTitle=利妥昔单抗联合苯达莫司汀或可治疗侵袭性B细胞淋巴瘤, objectType=article, longId=3000, objectId=35133000eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35133000eb, replyNumber=0, likeNumber=77, createdTime=2012-02-10, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35133000eb, moduleTitle=利妥昔单抗联合苯达莫司汀或可治疗侵袭性B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35133000eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

侵袭性B细胞淋巴瘤

2020-05-29

梅斯管理员

#循环肿瘤DNA# #侵袭性B细胞淋巴瘤#

【JAMA Oncol】循环肿瘤DNA在侵袭性B细胞淋巴瘤MRD评估中大有可为

2025-03-21发表于陕西省

梅斯管理员

#CAR-T# #侵袭性B细胞淋巴瘤#

【Hemasphere】CAR-T等新疗法显著改善了R/R侵袭性B细胞淋巴瘤生存：西班牙真实世界研究

2024-05-28发表于上海

梅斯管理员

#放疗# #侵袭性B细胞淋巴瘤#

【Leukemia】放疗可改善年轻高危侵袭性B细胞淋巴瘤患者预后

2024-04-03发表于陕西省

zhu_jun9837

#侵袭性B细胞淋巴瘤#

NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较

2022-07-11

zhu_jun9837

#侵袭性B细胞淋巴瘤#

Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后

2022-06-23

zhu_jun9837

#侵袭性B细胞淋巴瘤#

Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效

2021-09-26

zhu_jun9837

#侵袭性B细胞淋巴瘤#

Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效

2021-02-15

zhu_jun9837

#侵袭性B细胞淋巴瘤#

CLIN CANCER RES：克服侵袭性B细胞淋巴瘤Venetoclax耐药策略

2018-09-10

zhu_jun9837

#侵袭性B细胞淋巴瘤#

Lancet Haematol：MYC基因重排侵袭性B细胞淋巴瘤可考虑剂量调整的EPOCH-R方案

2019-04-01

zhu_jun9837

#侵袭性B细胞淋巴瘤#

MYC基因异常的侵袭性B细胞淋巴瘤

2015-01-01

zhu_jun9837

#侵袭性B细胞淋巴瘤#

Lancet Oncol：R-MegaCHOEP方案无益于年轻高危侵袭性B细胞淋巴瘤患者（(DSHNHL 2002-1研究）

2013-04-09

zhu_jun9837

#侵袭性B细胞淋巴瘤#

利妥昔单抗联合苯达莫司汀或可治疗侵袭性B细胞淋巴瘤

2012-02-10